Pricing

Sana Biotechnology Inc (SANA)

followers ยท
Sector: HEALTH CARE
Industry: BIOTECHNOLOGY & LIFE SCIENCES
CEO: Steven D. Harr
Employees: 380
Web site: sana.com
188 EAST BLAINE STREET, SUITE 400, SEATTLE, WA, 98102
(206) 701-7914
All 13F Filers Prior Change Hedge Funds 1 Prior Change
Sana Biotechnology, Inc. focuses on utilizing engineered cells as medicines. Its product candidates include SG295 and SG242 that target CD19+ cancer cells, including non-Hodgkin Lymphoma, chronic lymphocytic leukemia, and acute lymphoblastic leukemia. SC291, a CD19 allogeneic T cell therapy; SC255 for multiple myeloma; SC451 for type I diabetes mellitus. SC379 for secondary progressive multiple sclerosis, Pelizaeus-Merzbacher disease, and Huntington's disease.
Please log in first to see chart
InvestorHistoryShares Held or Principal AmtMarket Value% of PortfolioPrevious % of PortfolioRankChange in Shares% Change in Shares% OwnershipQtr 1st OwnedEst. Avg PriceSourceSource DateDate Reported
No data available